Showing 4971-4980 of 8839 results for "".
- Soliton Seeks 510k Clearance for RAP Anti-Cellulite Devicehttps://practicaldermatology.com/news/soliton-seeks-510-clearance-for-rap-anti-cellulite-device/2460452/Soliton, Inc. filed for 510(k) premarket clearance with the U.S. Food and Drug Administration (FDA) of its second-generation Rapid Acoustic Pulse (RAP) device for the reduction in the appearance of cellulite. The RAP device was previously cleared by the FDA as an accessory to a 1064 nm
- AOBiome Initiates Phase 2b Clinical Trial of B244 in Adults with ADhttps://practicaldermatology.com/news/aobiome-initiates-phase-2b-clinical-trial-of-b244-in-adults-with-ad/2460450/AOBiome Therapeutics, Inc. is initiating a Phase 2b clinical trial of its lead product candidate, B244, in pruritus associated with atopic dermatitis. B244 is a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria that is delivered as a spray twice daily for 28 d
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten
- Arcutis: Enrollment Complete for Phase 2 Study of Roflumilasthttps://practicaldermatology.com/news/arcutis-enrollment-complete-for-phase-2-study-of-roflumilast/2460446/Enrollment is now complete for the Phase 2 proof of concept clinical trial evaluating roflumilast foam for the treatment of seborrheic dermatitis. Arcutis Biotherapeutics is developing roflumilast, a selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor), in a once-daily topical
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- FDA Approves New Dupixent Pre-filled Pen Designed to Support More Convenient Self-Administrationhttps://practicaldermatology.com/news/fda-approves-new-dupixent-pre-filled-pen-designed-to-support-more-convenient-self-administration/2460444/The FDA has approved a 300mg single-dose pre-filled pen for Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma
- Acne News: Clascoterone Cream 1% Exhibits Long-Term Safety for Treatment of Acnehttps://practicaldermatology.com/news/acne-news-clascoterone-cream-1-exhibits-long-term-safety-for-treatment-of-acne/2460442/Cassiopea SpA’s Clascoterone cream 1% is safe for the treatment of acne with low rates of treatment-related adverse events, according to a study in the online issue of
- Tralokinumab Achieves Primary and Secondary Endpoints in Three pivotal Phase 3 Trials for ADhttps://practicaldermatology.com/news/tralokinumab-achieves-primary-and-secondary-endpoints-in-three-pivotal-phase-3-trials-for-ad/2460440/LEO Pharma A/S, shared results showing that tralokinumab 300mg, administered subcutaneously every two weeks, demonstrated efficacy and safety with or without concomitant use of a topical corticosteroid (TCS) in three Phase 3 trials (ECZTRA 1-3) for the treatment of adults with moderate to severe